Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESKUE
NCT04693598Phase 2Active, not recruiting
- Sponsor
- Forge Biologics
- Start
- Nov 2021
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of FBX-101 in Krabbe disease (2 cohorts), sponsored by Forge Biologics. Primary endpoints: Adverse Events at 24 months and Hematopoietic Stem Cell Transplantation Engraftment at 24 months. Started Nov 2021; status: active, not recruiting.
02
Drugs
FBX-101
03
Conditions
Krabbe disease
Beyond the preview
Go deeper on NCT04693598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04693598.